Abu Dhabi Health Services Co.

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE). Additionally, at the conference Napo is sponsoring a panel discussion titled "Masterclass in Congenital Diarrhea" which will focus on microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder. Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for both MVID and short bowel syndrome (SBS) with intestinal failure. "As previously announced, Jaguar, with strong leadership and participation from Jaguar family companies Napo Pharmaceuticals and Napo Therapeutics, is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of MVID and SBS with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected in 2024. Additionally, in August 2023 the FDA activated Napo Pharmaceuticals' Investigational New Drug (IND) application for a novel formulation of crofelemer for the treatment of MVID, which allows us to initiate our planned phase 2 trial of crofelemer for treatment of this indication in pediatric MVID patients," said Lisa Conte, Jaguar's president and CEO. "In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases could support early patient access to crofelemer for these debilitating conditions in those countries." MVID is a severe infantile disease characterized by diarrhea, malabsorption, and acid/base instability, requiring intensive parenteral support for nutritional and fluid management, and there are currently no approved drug treatments. Dr. Mohamad Miqdady, a member of Napo's Scientific Advisory Board (SAB), will serve as the moderator of the Napo-sponsored panel discussion. The session panelists include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of the Napo SAB, as well as Dr. Christos Tzivinikos and Dr. Antonella Diamanti, who are leading experts in the treatment of MVID patients in the UAE and Italy. Dr. Miqdady is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi. He is also an Adjunct Professor at Khalifa University's medical school in Abu Dhabi, and completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston. Dr. Christos Tzivinikos is a Consultant Pediatric Gastroenterologist and Founder of the Pediatric GI Department at Al Jalila Children's Specialty Hospital in Dubai, and an Adjunct Clinical Assistant Professor at Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai. Dr. Diamanti is Head of the Artificial Nutrition Unit at Bambino Gesù Children's Hospital in Rome, Italy. She has served as Medical Director of the hospital's Gastroenterology Department since 2001. Dr. Tzivinikos and Dr. Diamanti will be clinical investigators in Napo's planned phase 2 MVID study, titled Evaluation of Safety, Tolerability and Efficacy of Crofelemer Following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants with Microvillus Inclusion Disease (MVID). About the Elite Ped-GI Congress This Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders. The annual event provides a venue for healthcare professionals to share their best practices, to network within groups of interest, and to create and strengthen clinical collaborations. Additional information about the Elite Ped-GI Congress can be viewed here on the event website. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing innovative, patient-centric therapeutic solutions for essential supportive care and the management of neglected side effects across complicated disease states. Napo's goal is to redefine what is possible in supportive care, providing hope and improving outcomes for patients worldwide. Napo's crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit napotherapeutics.com Magdalena Biosciences, visit magdalenabiosciences.com Visit Jaguar on LinkedIn: Visit Jaguar on X: Visit Jaguar on Instagram: Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that results from investigator-initiated and IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure will be available in 2024, the expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations of crofelemer for MVID and SBS could support early patient access to crofelemer for these rare diseases in those countries, and the expectation that Jaguar will conduct a phase 2 clinical study of crofelemer for the treatment of MVID. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Source: Jaguar Health, Inc. Contact: hello@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on accesswire.com

Healthcare mergers and acquisitions are in no short supply as providers, retailers, health tech companies and other industry players look to expand their businesses and gain a competitive edge. Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. Here’s a roundup of new deals that were revealed, closed, rumored or called off during the month of March. Providers Aspirus Health and St. Luke’s Duluth have closed their merger. The new nonprofit is a 19-hospital entity with 130 outpatient locations spread across Minnesota, Wisconsin and Michigan's Upper Peninsula. It is maintaining Aspirus’ brand name. Tenet Healthcare wrapped up a pair of California hospital divestitures in the final week of March. The first was for four hospitals and related outpatient sites in Southern California, for which UCI Health paid $975 million. The second involved two central California hospitals and their related locations, which Adventist Health picked up for $550 million. Kaiser Permanente's value-based care platform, Risant Health, closed its acquisition of Geisinger Health on March 31. The deal is the first part of Kaiser's national expansion plan, which will involve another "four to five" regional health system acquisitions within the next half decade. Ascension has a definitive agreement in place to offload three northern Michigan hospitals and other facilities to MyMichigan Health. The deal is still subject to regulatory and other third-party approvals but is expected to close this summer. Financial terms of the deal were not disclosed. Steward Health Care is planning to sell off its physician group to UnitedHealth Group’s Optum in order to right its struggling finances. A sale price was not disclosed. Massachusetts’ Health Policy Commission is currently reviewing the deal, which could close during the second quarter. Prominent antitrust lawmakers have already expressed concerns about Optum’s involvement. Optum’s Oregon division has been granted emergency regulatory approval to acquire Corvallis Clinic. Optum was permitted to bypass state review in order to preserve the provider’s financial solvency, which was strained due to service interruptions at Optum’s sister business, Change Healthcare. UCLA Health acquired a 260-bed hospital and its related assets from HCA Healthcare. UCLA said it has “retained the vast majority of healthcare professionals and support staff” that previously worked at the hospital. West Virginia University Health System has signed a letter of intent to acquire Weirton Medical Center, a 238-bed facility with more than 50 ancillary locations around West Virginia, eastern Ohio and western Pennsylvania. The organizations are targeting a Jan. 1, 2025 close. Walgreens-owned VillageMD sold 11 primary care clinics in Rhode Island to Boston-based Arches Medical Partners for an undisclosed sum. Walgreens has recently exited 140 locations and in the midst of shuttering about 100 more. Pennsylvania Mountains Care Network and Armstrong County Memorial Hospital have signed a definitive agreement for the hospital to join the network. Mayo Clinic reportedly sold its 25% stake in Sheikh Shakhbout Medical City, a 741-bed hospital in the United Arab Emirates, to Abu Dhabi Health Services Co., for $150 million. Mayo Clinic had initially invested $50 million of cash and other nonmaterial assets. Sutter Health acquired five California radiation oncology centers from GenesisCare for an undisclosed sum. Payers Elevance Health has a deal in place to acquire Kroger Specialty Pharmacy sometime in the back half of 2024. Financial terms of the purchase, which requires regulatory approvals, were not disclosed. Elevance said it intends to add the grocery chain’s business unit to CarelonRx, which houses its pharmacy benefit management services. Elevance Health also closed a previously announced deal to acquire Paragon Healthcare, a Plano, Texas-based company specializing in infusible and injectable drug therapies. Paragon patients will receive medical and pharmacy benefits from Elevance Health subsidiaries and operate within CarelonRx, while Elevance aims to expand the group’s geographical footprint. Financial terms were not disclosed. UnitedHealth Group’s plan to acquire home health provider Amedisys for $3.7 billion cash is under investigation by the Oregon Health Authority. The review will be completed within 180 days of the receipt of transaction forms, which were confirmed in December. Tech GTCR, a private equity firm, has sold RevSpring, a patient engagement and payment technology company, to fellow private equity firm Frazier Healthcare Partners as well as New Enterprise Associates, 22C Capital and RevSpring’s leadership team. Financial terms were not disclosed, though Frazier said it plans to grow the end-to-end platform beyond its current scale of $8 billion in annually processed payments. WebMD, an online healthcare information provider, acquired the operating assets of Healthwise to bolster its patient and member engagement tools. The pickups will be folded into WebMD Ignite, its tech solutions brand. Financial terms were not disclosed. New Mountain Capital’s negotiations with investor coalition RCP-ASC to buy out R1 RCM were put on ice after a special committee of independent directors formed by the revenue cycle management company ordered them to cease discussions, according to a Securities and Exchange Commission filing. Innovaccer, a healthcare data and AI company, acquired Pharmacy Quality Solutions, a pharmacy-payer performance technology company, for an undisclosed sum. Innovaccer said the deal supports its goal of accelerating value-based care and extends its reach among community pharmacies. Terms were not disclosed. QuickMD, a telemedicine addiction treatment provider, acquired addiction treatment clinic Project Recover for an undisclosed sum. The company said its purchase will expand its reach and impact. Syllable Corporation, a process automation vendor, purchased EHR analysis company Actium Health for an undisclosed sum. With Actium under its wing, Syllable said it will be able to flesh out its automation offerings for health systems. Sagility acquired healthcare call center automation tech startup BirchAI for an undisclosed sum. Carenet Health, a patient engagement and navigation company, acquired all assets of population health management technology company Health Dialog from Rite Aid. Terms were not disclosed. Healthy Together, a SaaS vendor for government programs, acquired predictive insights platform Kinsa Health for an undisclosed sum. Mahana Therapeutics, a digital chronic disease management program maker, acquired digital digestive health company Cara Care (HiDoc Technologies GmbH) to accelerate its market entry in Europe, where it says reimbursement for the offerings outpaces that of the U.S. Financial terms were not disclosed. Miscellaneous Healthpeak Properties and Physicians Realty Trust, both healthcare real estate companies, closed their previously announced $21 billion merger. The new company operates under the name Healthpeak Properties and is trading on the New York Stock Exchange. Sila Realty Trust, a real estate investment trust, acquired four micro-hospitals and a freestanding emergency department for $85.5 million. The facilities are located in Arizona and Texas and are leased by Tenet Healthcare.

PureHealth listing marks ADX's 6th IPO in 2023 and raised a total of $986 million (AED 3.62 billion). The total value of IPOs on ADX in 2023 stood at $5.57 billion ABU DHABI, UAE, Dec. 20, 2023 /PRNewswire/ -- Abu Dhabi Securities Exchange (ADX), one of the fastest growing exchanges in the world, welcomed today the listing of PureHealth, the largest integrated healthcare platform in the Middle East. PureHealth's Initial Public Offering (IPO) raised a total of AED 3.62 billion ($986 million) and was oversubscribed by 483 times in the retail tranche and by 54 times in the professional subscribers tranche. This listing also marks the 6th IPO on ADX this year. The total value of IPOs on ADX in 2023 stood at $5.57 billion. Continue Reading PureHealth Listing Day Commenting on the listing, Abdulla Salem Alnuaimi, Chief Executive Officer of ADX, said: "We warmly welcome PureHealth to the ADX family and look forward to their invaluable contribution towards the healthcare services sector in the UAE and beyond. This year, we have witnessed strong investors' interest and participation towards the various dynamic listings and initiatives on the ADX platform. We aim to continuously strengthen our market infrastructure and trading offerings and investment services to enable more local and global companies to achieve their capital raising and investment ambitions. At ADX, we are committed to fulfilling Abu Dhabi's economic strategy and expanding the sustainable growth and development of capital markets in the UAE and wider Middle East region." PureHealth joins a growing group of both local and global healthcare service providers on ADX, demonstrating the Exchange's role as a hub for healthcare investments and providing opportunities for the exchange's investors to further diversify their portfolios. The company's global footprint in the United States and the United Kingdom reflects the growing internationalization of ADX and highlights ADX's active role in augmenting Abu Dhabi's economic growth and diversification. Farhan Malik, Founder and Managing Director of PureHealth, said, " PureHealth's listing on ADX has surpassed IPO records on the exchange, making this a significant milestone in our journey. As the largest integrated healthcare platform in the Middle East, we are proud of the role we continue to play in shaping the healthcare sector for Abu Dhabi and beyond. We will continue to transform healthcare, in line with the vision of Abu Dhabi's leadership, together delivering accessible, world-class healthcare backed by the latest in AI technology and supported by continued public and private sector collaboration. PureHealth is now becoming into a healthcare equity platform where our focus will be on international expansion. This listing will further support our equity growth story by enabling us in taking the organization from Abu Dhabi to the World." PureHealth IPO rounds out a strong year for ADX. Some notable listings in 2023 include the largest-ever IPO on ADX of ADNOC Gas at $2.5 billion, ADIB's world's first Dollar-denominated sukuk with $500 million value of issuance, the IPO of Presight AI at approximately $496 million, to name a few. About Abu Dhabi Securities Exchange Abu Dhabi Securities Exchange (ADX) was established on November 15, 2000, by Local Law No. (3) Of 2000, the provisions of which vest the market with a legal entity of autonomous status, independent finance and management. The Law also provides ADX with the necessary supervisory and executive powers to exercise its functions. On March 17, 2020, ADX was converted from a "Public Entity" to a "Public Joint Stock Company PJSC" pursuant to law No. (8) of 2020. ADX is part of ADQ, one of the region's largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi's diversified economy. ADX is a market for trading securities; including shares issued by public joint stock companies, bonds issued by governments or corporations, exchange traded funds, and any other financial instruments approved by the UAE Securities and Commodities Authority (SCA). ADX is the second largest market in the Arab region and its strategy of providing stable financial performance with diversified sources of incomes is aligned with the guiding principles of the UAE "Towards the next 50" agenda. The national plan charts out the UAE's strategic development scheme which aims to build a sustainable, diversified and high value-added economy that positively contributes to transition to a new global sustainable development paradigm. For more information, please contact: ADX Abdulrahman Saleh ALKhateeb Manager of Corporate Communication Mobile: +971 (50) 668 9733 Email: [email protected] About PureHealth By advancing the science of longevity, PureHealth is introducing the healthcare of the future from the UAE to the rest of the world. PureHealth is the largest integrated healthcare platform in the Middle East, with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centers, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare, as the company is on a mission to unlock time for humankind. PureHealth's network of healthcare facilities across Abu Dhabi and the Northern Emirates comprises: • SEHA – Abu Dhabi Health Services Company – One of the largest healthcare networks of hospitals and clinics in the UAE • Daman – The National Health Insurance Company, the UAE's leading health insurer • The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. the President of the UAE • Rafed – The UAE's largest healthcare Group Purchasing Organization • PureLab – Managing and operating the largest network of laboratories in the region • Abu Dhabi Stem Cells Center – Specialist healthcare center focused on cell therapy and regenerative medicine • One Health – Sales, service support, and engineering network that provides end-to-end medical solutions • The Life Corner – Abu Dhabi's first holistic pharmacy, serving the health and wellness establishment • Ardent - The fourth largest privately held acute care hospital operator in the USA Photo - SOURCE PureHealth